<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>immunotherapies Arkiv - NHTA</title>
	<atom:link href="https://nhta.com/tag/immunotherapies/feed/" rel="self" type="application/rss+xml" />
	<link>https://nhta.com/tag/immunotherapies/</link>
	<description></description>
	<lastBuildDate>Thu, 30 Apr 2026 10:31:00 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.5</generator>

<image>
	<url>https://nhta.com/wp-content/uploads/2025/06/favicon-150x150.png</url>
	<title>immunotherapies Arkiv - NHTA</title>
	<link>https://nhta.com/tag/immunotherapies/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Breaking: Denmark speeds up access to PD-(L)1 immunotherapies</title>
		<link>https://nhta.com/breaking-denmark-speeds-up-access-to-pd-l1-immunotherapies/</link>
		
		<dc:creator><![CDATA[NHTA]]></dc:creator>
		<pubDate>Thu, 30 Apr 2026 10:31:00 +0000</pubDate>
				<category><![CDATA[Insights]]></category>
		<category><![CDATA[immunotherapies]]></category>
		<category><![CDATA[medicinrådet]]></category>
		<category><![CDATA[pd-(l)1]]></category>
		<guid isPermaLink="false">https://nhta.com/breaking-denmark-speeds-up-access-to-pd-l1-immunotherapies/</guid>

					<description><![CDATA[<p>Cancer patients get faster access to certain PD-(L)1 immunotherapies in Denmark. Inspired by the NT-Council in Swden, The Danish Medicines Council has adopted a new, simplified process for PD-(L)1 inhibitors in locally advanced inoperable or metastatic cancer, meaning many patients can start treatment within 10 days after marketing authorisation. Key facts from the announcement: The...</p>
<p>Indlægget <a href="https://nhta.com/breaking-denmark-speeds-up-access-to-pd-l1-immunotherapies/">Breaking: Denmark speeds up access to PD-(L)1 immunotherapies</a> blev først udgivet på <a href="https://nhta.com">NHTA</a>.</p>
]]></description>
										<content:encoded><![CDATA[<h1><strong>Cancer patients get faster access to certain PD-(L)1 immunotherapies in Denmark. </strong></h1>
</p>
<p>Inspired by the NT-Council in Swden, <strong>The Danish Medicines Council</strong> has adopted a new, simplified process for PD-(L)1 inhibitors in <strong>locally advanced inoperable or metastatic cancer</strong>, meaning many patients can start treatment <strong>within 10 days after marketing authorisation</strong>.</p>
</p>
<p><strong>Key facts from the announcement:</strong></p>
</p>
<ul>
<li>
<p>The prior individual assessment (fast-track) process typically took <strong>around 14 weeks</strong>.</p>
</li>
</ul>
<ul>
<li>
<p>Under the new model, new PD-(L)1 drugs and eligible indication extensions are combined into a <strong>common, general recommendation</strong> for the whole class (instead of case-by-case review).</p>
</li>
</ul>
<ul>
<li>
<p><strong>(Neo)adjuvant and perioperative indications</strong> are still assessed via Medicinrådet’s <strong>14-week</strong> process.</p>
</li>
</ul>
<ul>
<li>
<p>The simplified model applies when the PD-(L)1 inhibitor is used as <strong>monotherapy</strong> or with <strong>non-patent-protected</strong> medicines, and when <strong>one-year drug costs</strong> are in line with others in the class (accepted annual price threshold).</p>
</li>
</ul>
<p>The model takes effect <strong>1 June</strong> and will be <strong>evaluated after one year</strong>.</p>
</p>
<p>Having developed an extensive number of applications following the 14-week process, NHTA will follow this closely and it will be interesting to see the impact this change will generate (timelines, patient impact, budget impact, competition, etc.)</p>
</p>
<p>Read more at <a target="_blank" rel="noopener noreferrer nofollow" href="https://medicinraadet.dk/nyheder/2026/kraeftpatienter-far-hurtigere-adgang-til-ny-immunterapi">https://medicinraadet.dk/nyheder/2026/kraeftpatienter-far-hurtigere-adgang-til-ny-immunterapi</a></p>
<p>Indlægget <a href="https://nhta.com/breaking-denmark-speeds-up-access-to-pd-l1-immunotherapies/">Breaking: Denmark speeds up access to PD-(L)1 immunotherapies</a> blev først udgivet på <a href="https://nhta.com">NHTA</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
